Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01749878 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and Tolerability of Single Doses of REGN1500
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT01749878 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 99 participants.
The verdict
NCT01749878, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
Phase 1, first-in-human, randomized, ascending single-dose, placebo-controlled, double-blind study of the safety, tolerability, and bioeffect of REGN1500
Interventions
- DRUG placebo
- DRUG REGN1500
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2012-12 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01749878
The ClinicalTrials.gov registry entry for NCT01749878 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01749878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01749878 about?
NCT01749878 is a clinical study titled "Study to Assess the Safety and Tolerability of Single Doses of REGN1500". Phase 1, first-in-human, randomized, ascending single-dose, placebo-controlled, double-blind study of the safety, tolerability, and bioeffect of REGN1500
What is the current status of trial NCT01749878?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2012-12. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01749878?
The interventions under investigation include: placebo (DRUG), REGN1500 (DRUG).
Who is sponsoring clinical trial NCT01749878?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.